A study found that treating patients with rivaroxaban for 45 days after hospital discharge reducedthe rate of nonfatal blood clots, but had no effect on fatal blood clots.
A massive retrospective study compared several non-vitamin K antagonist oral anticoagulants (NOACs) to warfarin.
Apixaban (Eliquis) had the lowest overall risks out of direct oral anticoagulants (DOACs) versus warfarin (Coumadin) in a large study.
Using oral anticoagulants and nonsteroidal anti-inflammatory drugs (NSAIDs) together increases the risk for major bleeding and stroke in patients with atrial fibrillation (AF), according to a new analysis.
A reversal agent to stop serious bleeding in patients treated with apixaban and rivaroxaban has been approved.
Oral rivaroxaban may be preferable to injections of low-molecular-weight heparins for patients being treated for cancer.
A study found that apixaban is a safe alternative to VKAs for ablation of atrial fibrillation.
Andaxanet alfa has shown effectiveness for patients needing hemostasis.
Three medical groups have issued guidelines for the use of anticoagulants during cardiac surgery.
The DOAC edoxaban can replace dalteparin for treating cancer patients with venous thromboembolism.